Aldesleukin Completed Phase 2 Trials for Recurrent Melanoma / Stage IV Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00726739Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00005949Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma